腎癌藥物市場 - 按癌症類型、治療方法、藥物類別、給藥途徑、配銷通路和全球預測

Kidney Cancer Drugs Market - By Cancer Type, Therapy, Drug Class, Route of Administration, Distribution Channel & Global Forecast 2024-2032

出版日期: 2024年06月25日 | 出版商:

Global Market Insights Inc. | 英文 110 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

在藥物開發和治療方案中越來越重視以患者為中心的方法的推動下，腎癌藥物市場規模從 2024 年到 2032 年的複合年成長率將達到 5.6%。

基因組分析和生物標記研究的最新進展正在為腎癌治療的個人化醫療鋪平道路。例如，2023年12月，HIF-2a抑制劑Belzutifan被美國FDA核准用於治療先前接受過抗血管新生療法和免疫檢查點抑制劑治療的晚期腎癌患者。開發具有成本效益的治療方法、實施定價策略和擴大保險覆蓋範圍的持續努力也將影響市場的成長。

腎癌藥物產業分為癌症類型、治療方法、藥物類別、給藥途徑、配銷通路和地區。

按癌症類型分類，腎母細胞瘤細分市場的行業價值將在2024 年至2032 年間出現利潤豐厚的成長。。為此，多家製藥公司正在開發和銷售針對兒童的藥物。治療兒科癌症的需求不斷成長，導致醫療基礎設施（例如專門的兒科腫瘤中心）得到改善，從而促進了該細分市場的成長。

就給藥途徑而言，預計到2032 年，靜脈注射腎癌藥物的市場規模將顯著擴大。中獲得更好的療效。腫瘤學家也更喜歡為某些患者提供靜脈注射藥物，尤其是那些由於口服藥物的副作用或其他醫療狀況而難以使用口服藥物的患者。

到 2032 年，在治療方案的快速進步和消費者意識不斷提高的帶動下，亞太地區腎癌藥物產業佔有率將實現大幅複合年成長率。對臨床試驗和研究計劃的大量投資正在導致針對該地區患者基因特徵的創新藥物的開發。腎癌發病率的飆升以及隨後對有效藥物的需求以及不斷成長的監管支持將有利於區域產品的吸收。

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 11 章：公司簡介

Active Biotech AB
Amgen, Inc.
Astellas Pharma Inc.
AstraZeneca PLC
Bayer AG
Bristol-Myers Squibb Company
Eisai Co., Ltd.
Exelixis, Inc.
F. Hoffmann-La Roche Ltd.
Genentech, Inc.
GSK plc
Helsinn Healthcare SA
Johnson & Johnson Services, Inc.
Merck & Co., Inc.
Novartis AG

簡介目錄

Product Code: 10004

Kidney Cancer Drugs Market size will record 5.6% CAGR from 2024-2032, driven by the growing emphasis on patient-centric approaches in drug development and treatment protocols.

The recent advances in genomic profiling and biomarker research are paving the way for personalized medicine in kidney cancer treatment. For instance, in December 2023, Belzutifan, a HIF-2a inhibitor, was approved by the U.S. FDA for treating patients suffering from advanced kidney cancer that was previously treated with anti-angiogenic therapies and immune checkpoint inhibitors. The rising efforts to develop cost-effective treatments, implement pricing strategies, and expand insurance coverage will also influence the market growth.

The kidney cancer drugs industry is segmented into cancer type, therapy, drug class, route of administration, distribution channel, and region.

By cancer type, the industry value from the Wilms tumor segment will register lucrative growth between 2024 and 2032. As Wilms tumor is a pediatric cancer, its treatment creates a specific demand for pediatric oncology drugs. To that end, several pharmaceutical companies are developing and marketing drugs tailored for children. This surging need to treat pediatric cancers is leading to improvements in healthcare infrastructure, such as specialized pediatric oncology centers, adding to the segment growth.

In terms of route of administration, the kidney cancer drugs market size from the intravenous segment is expected to record significant expansion through 2032. Intravenous (IV) administration allows effective delivery of higher concentrations of the drugs directly into the bloodstream, leading to better efficacy in treating advanced and metastatic kidney cancer. Oncologists also prefer IV drugs for certain patients, especially those who have difficulty with oral medications given their side effects or other medical conditions.

Asia Pacific kidney cancer drugs industry share will register substantial CAGR through 2032, led by rapid advances in treatment options and the increasing consumer awareness. Significant investments in clinical trials and research initiatives are leading to the development of innovative drugs tailored to the genetic profiles of patients in the region. The surging rate of kidney cancer incidence and the subsequent demand for effective drugs along with the growing regulatory support will favor the regional product uptake.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of kidney cancer
  - 3.2.1.2 Rising awareness and early diagnosis initiatives
  - 3.2.1.3 Technological advancements
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 High cost of treatment
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Pipeline analysis
3.6 Porter's analysis
3.7 PESTEL analysis
3.8 Future market trends

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Cancer Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Renal cell carcinoma (RCC)
5.3 Transitional cell cancer
5.4 Wilms tumor
5.5 Renal sarcoma

Chapter 6 Market Estimates and Forecast, By Therapy, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Targeted therapy
6.3 Immunotherapy
6.4 Chemotherapy
6.5 Other therapies

Chapter 7 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Angiogenesis inhibitors
7.3 Monoclonal antibodies
7.4 mTOR inhibitors
7.5 Cytokine immunotherapy (IL-2)
7.6 Other drug classes

Chapter 8 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Oral
8.3 Intravenous
8.4 Subcutaneous

Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 Hospital pharmacy
9.3 Brick and mortar
9.4 E-commerce

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

10.1 Key trends
10.2 North America
- 10.2.1 U.S.
- 10.2.2 Canada
10.3 Europe
- 10.3.1 Germany
- 10.3.2 UK
- 10.3.3 France
- 10.3.4 Spain
- 10.3.5 Italy
- 10.3.6 Netherlands
- 10.3.7 Rest of Europe
10.4 Asia Pacific
- 10.4.1 China
- 10.4.2 Japan
- 10.4.3 India
- 10.4.4 Australia
- 10.4.5 South Korea
- 10.4.6 Rest of Asia Pacific
10.5 Latin America
- 10.5.1 Brazil
- 10.5.2 Mexico
- 10.5.3 Argentina
- 10.5.4 Rest of Latin America
10.6 Middle East and Africa
- 10.6.1 South Africa
- 10.6.2 Saudi Arabia
- 10.6.3 UAE
- 10.6.4 Rest of Middle East and Africa